Newron Pharmaceuticals SpA, a specialist in central nervous system and pain therapies, has announced that it is participating in a consortium, led by Axxam SpA, that has been awarded a grant of €1 million by the Regione Lombardia (Metadistretti) towards a €2.5 million R&D programme aimed at identifying and developing sodium channel blockers for the treatment of pain.
The grant is non-refundable and covers R&D expenses over three years. Apart from Axxam, Newron’s partners in the consortium are Primm Srl., and academic groups at the University of Milan Bicocca.
Axxam, as Project coordinator, will provide its ion channel drug discovery platform, including target expression, proprietary high throughput technologies and screening libraries. Primm will provide expertise in protein expression and peptide chemistry, while Newron will contribute with its expertise in sodium channel electrophysiology and pain pharmacology.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
